secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeoVax Labs, Inc. (GOVX)
CIK:        0000832489
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001437749-25-023689
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeoVax Q2 net loss $5.4M; cash $3.1M; BARDA contract terminated; GEO-MVA gets EU guidance
--------------------------------------------------------------------------------

- Net loss $5.37M ($0.35/share) vs $5.06M ($1.99/share) in Q2 2024; per-share loss down on share dilution.
- Revenue from BARDA/RRPV contract $852k; BARDA terminated contract for convenience in Q2.
- Cash $3.09M at June 30; completed July 2025 public offering netting ~$5.6M.
- GEO-MVA received favorable EMA guidance allowing single Phase 3 immuno-bridging trial; trial expected 2H 2026.
- GEO-CM04S1 showed superior T-cell responses vs mRNA in CLL; mRNA arm failed endpoint, enrollment restricted to GEO-CM04S1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/0001437749-25-023689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/832489/000143774925023689/govx20250725_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-023689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer